Barclays
RCKT icon

Barclays’s Rocket Pharmaceuticals RCKT Stock Holding History

Barclays’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$377K – 5501
2024
Q4 		$377K Hold
30,000
– – ﹤0.01% 3991
2024
Q3 		$554K Buy
+30,000
New +$614K ﹤0.01% 3710
2024
Q2 		– Sell
-27,204
Closed -$733K – 5219
2024
Q1 		$733K Sell
27,204
-20,196
-43% -$574K ﹤0.01% 3343
2023
Q4 		$1.42M Buy
+47,400
New +$1.05M ﹤0.01% 3185

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's RCKT Position: Q1 2026 in Review

Barclays reduced its Rocket Pharmaceuticals (RCKT) stake by 89% in Q1 2026, selling an estimated $542K and leaving 16,578 shares worth $59.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4250.

Barclays first reported a position in RCKT in Q4 2015 and has held it in 41 quarters since. The position peaked at $9.59M in Q4 2021. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Barclays held 16,578 shares of Rocket Pharmaceuticals worth $59.4K as of Q1 2026.
  • Barclays sold 136,471 Rocket Pharmaceuticals shares in Q1 2026, an estimated $542K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4250 holding.
  • Barclays first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 41 quarters since.
  • Barclays's Rocket Pharmaceuticals position peaked at $9.59M in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.